Related Experiment Videos

New developments in the use of beta-blockers for the management of heart failure

Eliot H Ohlstein1, Anne M Romanic

  • 1GlaxoSmithKline, Cardiovascular and Urogenital Diseases CEDD, UW23-2032A, 709 Swedeland Road, King of Prussia, PA 19406, USA. eliot.h.ohlstein@gsk.com

Expert Opinion on Investigational Drugs
|July 23, 2004
PubMed

Insights

Beta-blockers are crucial for managing chronic heart failure (HF) by inhibiting the sympathetic nervous system. Combined with ACE inhibitors, they represent the superior medical intervention for HF patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (HF) is a growing healthcare concern in the US, driven by an aging population and better survival rates from acute coronary syndromes.
  • Increased sympathetic nervous system activity in HF patients impairs cardiovascular function and increases mortality risk.

Purpose of the Study:

  • To highlight the importance of effective heart failure management.
  • To emphasize the role of beta-blockers in mitigating sympathetic nervous system effects in HF.

Main Methods:

  • Review of clinical trials demonstrating the efficacy of beta-blockers.
  • Analysis of the neurohormonal pathway targeted by beta-blockers.

Main Results:

  • Beta-blockers, particularly when used with angiotensin-converting enzyme (ACE) inhibitors, have proven superior to other medical interventions for HF treatment.
  • Numerous clinical trials support the use of beta-blockers in HF management.

Conclusions:

  • Beta-blockers are essential for stabilizing HF patients and improving clinical symptoms.
  • The standard of care for HF now incorporates both beta-blockers and ACE inhibitors for optimal patient outcomes.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...